

Glioblastoma Multiforme Treatment-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/G5D8C4CD62FEN.html>

Date: January 2018

Pages: 147

Price: US\$ 3,480.00 (Single User License)

ID: G5D8C4CD62FEN

Abstracts

Report Summary

Glioblastoma Multiforme Treatment-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Glioblastoma Multiforme Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Glioblastoma Multiforme Treatment 2013-2017, and development forecast 2018-2023

Main market players of Glioblastoma Multiforme Treatment in Europe, with company and product introduction, position in the Glioblastoma Multiforme Treatment market
Market status and development trend of Glioblastoma Multiforme Treatment by types and applications

Cost and profit status of Glioblastoma Multiforme Treatment, and marketing status

Market growth drivers and challenges

The report segments the Europe Glioblastoma Multiforme Treatment market as:

Europe Glioblastoma Multiforme Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Glioblastoma Multiforme Treatment Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bevacizumab (Avastin)

Temozolomide (Temodar and Temodal and Temcad)

Carmustine (BiCNU)

Europe Glioblastoma Multiforme Treatment Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital

Clinic

Europe Glioblastoma Multiforme Treatment Market: Players Segment Analysis
(Company and Product introduction, Glioblastoma Multiforme Treatment Sales Volume,
Revenue, Price and Gross Margin):

AbbVie, Inc

Activartis GmbH

Agenus Inc

Arog Pharmaceuticals, Inc

Bristol-Myers Squibb Company

Cavion LLC

Celldex Therapeutics Inc

Cortice Biosciences

Exelixis Inc

F. Hoffmann-La Roche Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF GLIOBLASTOMA MULTIFORME TREATMENT

- 1.1 Definition of Glioblastoma Multiforme Treatment in This Report
- 1.2 Commercial Types of Glioblastoma Multiforme Treatment
 - 1.2.1 Bevacizumab (Avastin)
 - 1.2.2 Temozolomide (Temodar and Temodal and Temcad)
 - 1.2.3 Carmustine (BiCNU)
- 1.3 Downstream Application of Glioblastoma Multiforme Treatment
 - 1.3.1 Hospital
 - 1.3.2 Clinic
- 1.4 Development History of Glioblastoma Multiforme Treatment
- 1.5 Market Status and Trend of Glioblastoma Multiforme Treatment 2013-2023
 - 1.5.1 Europe Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023
 - 1.5.2 Regional Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Glioblastoma Multiforme Treatment in Europe 2013-2017
- 2.2 Consumption Market of Glioblastoma Multiforme Treatment in Europe by Regions
 - 2.2.1 Consumption Volume of Glioblastoma Multiforme Treatment in Europe by Regions
 - 2.2.2 Revenue of Glioblastoma Multiforme Treatment in Europe by Regions
- 2.3 Market Analysis of Glioblastoma Multiforme Treatment in Europe by Regions
 - 2.3.1 Market Analysis of Glioblastoma Multiforme Treatment in Germany 2013-2017
 - 2.3.2 Market Analysis of Glioblastoma Multiforme Treatment in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Glioblastoma Multiforme Treatment in France 2013-2017
 - 2.3.4 Market Analysis of Glioblastoma Multiforme Treatment in Italy 2013-2017
 - 2.3.5 Market Analysis of Glioblastoma Multiforme Treatment in Spain 2013-2017
 - 2.3.6 Market Analysis of Glioblastoma Multiforme Treatment in Benelux 2013-2017
 - 2.3.7 Market Analysis of Glioblastoma Multiforme Treatment in Russia 2013-2017
- 2.4 Market Development Forecast of Glioblastoma Multiforme Treatment in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Glioblastoma Multiforme Treatment in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Glioblastoma Multiforme Treatment by Regions

2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Glioblastoma Multiforme Treatment in Europe by Types

3.1.2 Revenue of Glioblastoma Multiforme Treatment in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Glioblastoma Multiforme Treatment in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Glioblastoma Multiforme Treatment in Europe by Downstream Industry

4.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Germany

4.2.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in France

4.2.4 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Italy

4.2.5 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Spain

4.2.6 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Benelux

4.2.7 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Russia

4.3 Market Forecast of Glioblastoma Multiforme Treatment in Europe by Downstream

Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

5.1 Europe Economy Situation and Trend Overview

5.2 Glioblastoma Multiforme Treatment Downstream Industry Situation and Trend Overview

CHAPTER 6 GLIOBLASTOMA MULTIFORME TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Glioblastoma Multiforme Treatment in Europe by Major Players

6.2 Revenue of Glioblastoma Multiforme Treatment in Europe by Major Players

6.3 Basic Information of Glioblastoma Multiforme Treatment by Major Players

6.3.1 Headquarters Location and Established Time of Glioblastoma Multiforme Treatment Major Players

6.3.2 Employees and Revenue Level of Glioblastoma Multiforme Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 GLIOBLASTOMA MULTIFORME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AbbVie, Inc

7.1.1 Company profile

7.1.2 Representative Glioblastoma Multiforme Treatment Product

7.1.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of AbbVie, Inc

7.2 Activartis GmbH

7.2.1 Company profile

7.2.2 Representative Glioblastoma Multiforme Treatment Product

7.2.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Activartis GmbH

7.3 Agenus Inc

7.3.1 Company profile

- 7.3.2 Representative Glioblastoma Multiforme Treatment Product
- 7.3.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Agenus Inc
- 7.4 Arog Pharmaceuticals, Inc
 - 7.4.1 Company profile
 - 7.4.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.4.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Arog Pharmaceuticals, Inc
- 7.5 Bristol-Myers Squibb Company
 - 7.5.1 Company profile
 - 7.5.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.5.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
- 7.6 Cavion LLC
 - 7.6.1 Company profile
 - 7.6.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.6.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cavion LLC
- 7.7 Celldex Therapeutics Inc
 - 7.7.1 Company profile
 - 7.7.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.7.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Celldex Therapeutics Inc
- 7.8 Cortice Biosciences
 - 7.8.1 Company profile
 - 7.8.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.8.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cortice Biosciences
- 7.9 Exelixis Inc
 - 7.9.1 Company profile
 - 7.9.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.9.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Exelixis Inc
- 7.10 F. Hoffmann-La Roche Ltd
 - 7.10.1 Company profile
 - 7.10.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.10.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 8.1 Industry Chain of Glioblastoma Multiforme Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 9.1 Cost Structure Analysis of Glioblastoma Multiforme Treatment
- 9.2 Raw Materials Cost Analysis of Glioblastoma Multiforme Treatment
- 9.3 Labor Cost Analysis of Glioblastoma Multiforme Treatment
- 9.4 Manufacturing Expenses Analysis of Glioblastoma Multiforme Treatment

CHAPTER 10 MARKETING STATUS ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Glioblastoma Multiforme Treatment-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/G5D8C4CD62FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5D8C4CD62FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970